SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TELK -- Telik, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (39)11/8/2000 5:26:45 PM
From: keokalani'nui  Read Replies (1) of 887
 
Some comments from the cc:

1. Assessment was performed at day 43 following treatment, responders continued. 11 continued. 6-week period per patient for evaluation from entry.

2. The longest (6 mo) response (stabilization) to date is in the NSCLC pt, consistent with high expression of GST in that disease.

3. Have not yet achieved MTD, but probably in sight. Seeing some Grade II toxicities, with Grade III the threshold for MTD. Doses going up by 30% over the 960/m2 until reached.

4. Unclear, but a potential dose response could be inferred in that the higher # of responders were in the 1x6 regimen. On track for p2 1Q01, in NSCLC, colorectal and ovarian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News